SCHEMBL19739512

SCHEMBL19739512

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COS(=O)(=O)OOS(=O)(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.69
TAS1R1 Q7RTX1 2/20 0.69
RXFP1 Q9HBX9 1/20 0.67
P2RY1 P47900 4/20 0.65
ADORA1 P30542 3/20 0.65
P2RY2 P41231 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
SRC P12931 2/20 0.65
DNPH1 O43598 1/20 0.65
PRKAB2 O43741 1/20 0.65
TRPM2 O94759 1/20 0.65
LDHA P00338 1/20 0.65
ADRB2 P07550 1/20 0.65
FBP1 P09467 1/20 0.65
PRKAG1 P54619 1/20 0.65
PRKAA2 P54646 1/20 0.65
PDE4D Q08499 1/20 0.65
KCNH2 Q12809 1/20 0.65
PRKAA1 Q13131 1/20 0.65
PDE3A Q14432 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30528063 1.00 TAS1R3 (0.69) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL29754360 0.91 TAS1R3 (0.75) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL1066377 0.91 TAS1R3 (0.75) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL8954219 0.91 TAS1R3 (0.75) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL30208039 0.88 CA1 (0.73) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL14201601 0.88 CA1 (0.73) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL2294870 0.88 CA1 (0.73) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL2294876 0.88 CA1 (0.73) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL11459665 0.86 ADORA1 (0.71) TAS1R3TAS1R1RXFP1P2RY1ADORA1
SCHEMBL4300880 0.86 P2RY1 (0.75) TAS1R3TAS1R1P2RY1ADORA1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109072286-B Method for cell lysis and nucleic acid amplification 3M创新有限公司 2023-08-11 CN disclosed
US-11168352-B2 Process for cell lysis and nucleic acid amplification 3M INNOVATIVE PROPERTIES COMPANY (US) 2021-11-09 US disclosed
EP-3594342-B1 COMPOSITION FOR REDUCING INHIBITION OF NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES CO (US) 2021-11-03 EP disclosed
CN-107980065-B Compositions for reducing inhibition of nucleic acid amplification 3M创新有限公司 2021-09-07 CN disclosed
EP-3294905-B1 COMPOSITION FOR REDUCING INHIBITION OF NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES CO (US) 2021-06-23 EP disclosed
EP-3440223-B1 PROCESS FOR CELL LYSIS AND NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES CO (US) 2020-12-23 EP disclosed
CN-107109402-B Compositions for reducing inhibition of nucleic acid amplification 3M创新有限公司 2020-09-25 CN disclosed
US-10619189-B2 Composition for reducing inhibition of nucleic acid amplification 3M INNOVATIVE PROPERTIES COMPANY (US) 2020-04-14 US disclosed
US-10604787-B2 Composition for reducing inhibition of nucleic acid amplification 3M INNOVATIVE PROPERTIES COMPANY (US) 2020-03-31 US disclosed
EP-3237637-B1 COMPOSITION FOR REDUCING INHIBITION OF NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES CO (US) 2019-09-04 EP disclosed
US-20190112637-A1 PROCESS FOR CELL LYSIS AND NUCLEIC ACID AMPLIFICATION JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2019-04-18 US disclosed
CN-109072286-A The method of cell cracking and nucleic acid amplification 3M创新有限公司 2018-12-21 CN disclosed
US-20180142280-A1 COMPOSITION FOR REDUCING INHIBITION OF NUCLEIC ACID AMPLIFICATION JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-05-24 US disclosed
US-20170369929-A1 COMPOSITION FOR REDUCING INHIBITION OF NUCLEIC ACID AMPLIFICATION 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-12-28 US disclosed